Special Member
Bedaquiline is a diarylquinoline drug that specifically targets the energy metabolism of tuberculosis bacteria by inhibiting ATP synthase, effectively cutting off their energy supply. It was the first new anti-TB drug in 40 years and is effective against multidrug-resistant TB.
